Search clinical trials for: Ibrutinib (Treatment B)

Total 17745 results

Janssen Research & Development, LLC

Completed

Study to Assess the Bioequivalence of Ibrutinib 560- Milligram (mg) Tablet to Four 140 -mg IMBRUVICA Capsules

Healthy

United States
Janssen Research & Development, LLC

Completed

A Crossover Study to Evaluate the Bioavailability of Ibrutinib Suspension and Sprinkle Formulations Compared to Capsules in Healthy Adults

Healthy

Belgium
Stichting Hemato-Oncologie voor Volwassenen Nederland
Nordic CLL Study Group

Active, not recruiting

A Prospective, Multicenter, Phase-II Trial of Ibrutinib Plus Venetoclax in Patients With Creatinine Clearance >= 30 ml/Min Who Have Relapsed or Refractory Chronic Lymphocytic Leukemia (RR-CLL) With or Without TP53 Aberrations

Chronic Lymphocytic Leukemia in Relapse | Chronic Lymphocytic Leukemia in Remission

Netherlands, Belgium, Denmark, Finland, Norway, Sweden
Pfizer

Completed

A Bioequivalence (BE) Study Comparing The Commericializable And Clinical Formulations Of PF-00299804

Healthy Volunteers

Belgium
French Innovative Leukemia Organisation
Janssen, LP

Active, not recruiting

Evaluation of the Safety and Efficacy of the Association of Ibrutinib and Daratumumab in Relapsed/Refractory Chronic Lymphocytic Leukemia With p53 Dysfunction (IDA53)

Relapsed or Refractory Chronic Lymphocytic Leukemia

France
Pfizer

Completed

A Study To Compare The Amount Of CP-690,550 That Is Absorbed Into The Blood Of Healthy Subjects Following Oral Administration Of Two Different Strength Tablets Of CP-690,550

Arthritis, Rheumatoid

Singapore
Pfizer

Completed

A Study to Estimate the Time Course of PF-00241939 Concentration in the Blood Following Dosing by Oral Inhalation From Dry Powder Inhalers (B0871003)

Pharmacokinetics

Singapore
Hospices Civils de Lyon

Completed

Rehabilitation For Acquired Visual Field Defects: Development Of A Bottom-Up Approach (VISIOTRAIN)

Acquired Visual Field Defects

France
Pfizer

Completed

Study To Assess The Pharmacokinetics Of 2 Different Formulations Of PF-04991532

Healthy

United States
Novartis Pharmaceuticals

Completed

Investigate Bioequivalence of Alpelisib Granule and Film-coated Tablet Formulation and the Food Effect of Alpelisib Granule Formulation in Adult Healthy Volunteers

Healthy Volunteers

United Kingdom
Pfizer

Completed

Study To Estimate The Time Course Of PF-04764793 In The Blood Following Dosing By Oral Inhalation From Dry Powder Inhalers

Healthy

Singapore
Rennes University Hospital

Recruiting

P-glypoprotein Inhibition Effect on the Pharmacokinetics of Two Tacrolimus Formulations: Prolonged and Extended-release (DIPLOID)

Pharmacokinetics

France
AstraZeneca
Parexel

Completed

A Study to Assess the Drug Absorption Into the Blood After Administration of 3 Doses of AZD5718

Coronary Artery Disease

United Kingdom
Pfizer

Completed

A Study To Estimate The Time Course Of PF-00241939 Concentration In The Blood Following Dosing By Oral Inhalation From Dry Powder Inhalers. (B0871002)

Healthy

Singapore
Christian Buske
Amgen; Janssen, LP

Recruiting

Efficacy and Safety of Carfilzomib in Combination With Ibrutinib vs Ibrutinib in Waldenström's Macroglobulinemia (CZAR-1)

Waldenstrom Macroglobulinemia

Austria, Germany, Greece
Altamira Medica Ltd.

Completed

Efficacy and Safety of AM-301 on Allergic Symptoms of Perennial Allergic Rhinitis Sufferers

Rhinitis, Allergic | Perennial Allergic Rhinitis

Canada
JW Pharmaceutical

Completed

To Evaluate the Pharmacokinetic Drug Interactions, Safety and Drug Tolerance in Healthy Volunteers

Healthy

Korea, Republic of
Pfizer

Completed

A Study To Estimate The Relative Bioavailability Of PF-00258210 Administered Alone Or In Combination With PF-00610355

Asthma

Singapore
TG Therapeutics, Inc.

Completed

Ublituximab + Ibrutinib in Select B-cell Malignancies

Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia

United States
Alexion Pharmaceuticals
Parexel

Completed

Bioequivalence Between 180 mg and 60 mg ALXN2050 Tablets and Food Effect on ALXN2050 Pharmacokinetics

Healthy Adult Participants

United States
Chiesi Farmaceutici S.p.A.

Completed

PK Linearity and Steady State PK of CHF 6532 in Healthy Subjects

Asthma

Belgium
Chiesi Farmaceutici S.p.A.

Terminated

Efficacy and Safety of CHF 6532 in Patients With Uncontrolled Severe Eosinophilic Asthma (PERSEA)

Asthma; Eosinophilic

Bulgaria
Pharmacyclics LLC.
Janssen Research & Development, LLC

Completed

Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States, Australia, Belgium, Canada, China, Czechia, Ireland, Israel, Italy, New Zealand, Poland, Russian Federation, Spain, Turkey, Ukraine, United Kingdom
Grupo Argentino de Tratamiento de la Leucemia Aguda

Not yet recruiting

Ibrutinib Adapted to Response in Patients With CLL

Chronic Lymphocytic Leukemia
AstraZeneca

Completed

A Study to Assess the Effect of Particle Size of AZD7594 on Pharmacokinetics (PK) After a Single Inhaled Dose When Administered Using the Dry Powder Inhaler in Healthy Volunteers

Asthma, Chronic Obstructive Pulmonary Disease (COPD)

Germany
Pfizer

Completed

A Study To Estimate The Time Course Of PF-00241939 Concentration In The Blood After Dosing With Oral Inhalation From Dry Powder Inhalers

Pharmacokinetics

Singapore
Celltrion

Completed

A Drug-Drug Interaction Study of CTL0901 and CTL0902 Compared to Coadministration in Healthy Adult Volunteers

Health, Subjective

Korea, Republic of
Pfizer

Completed

This Study Is To Estimate The Time Course Of Pf-04764793 In The Blood Following Dosing By Oral Inhalation From Dry Powder Inhalers

Healthy

Singapore
Johnson & Johnson Private Limited

Completed

A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion

Lymphoma, Mantle-Cell | Leukemia, Lymphocytic, Chronic, B-Cell

India
Taejoon Pharmaceutical Co., Ltd.

Active, not recruiting

A Phase 3 Clinical Trials for Bowel Preparation for Colonoscopy

Bowel Preparation

Korea, Republic of
Oncternal Therapeutics, Inc
University of California, San Diego; Pharmacyclics LLC.; California Institute...

Active, not recruiting

A Study of Cirmtuzumab and Ibrutinib in Patients With B-Cell Lymphoid Malignancies

Mantle Cell Lymphoma | Marginal Zone Lymphoma | B-cell Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

United States
Biogen

Completed

New Formulation and Food Effect Study of BIIB074

Trigeminal Neuralgia (TN) | Other Neuropathic Pain

United States
The Lymphoma Academic Research Organisation
Janssen Pharmaceutica N.V., Belgium

Terminated

Bruton's Tyrosine Kinase (BTK) Inhibition in B-cell Lymphomas (BIBLOS)

B-cell Lymphoma

France, Belgium
Pfizer

Completed

A Study Estimating The Time Course Of PF-04764793 In The Blood Following Dosing By Oral Inhalation From Dry Powder Inhalers

Healthy

Singapore
Daiichi Sankyo, Inc.

Completed

Food Effects on Milademetan Pharmacokinetics in Healthy Participants

Food Effects on Pharmacokinetics

United States
Bayer

Completed

Comparison of the Extent to Which the Drug Given as Two Different Capsule Sizes Becomes Available to the Body

Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women and Men

Germany
Pfizer

Completed

A Study To Evaluate The Effect Of Food On How Tasocitinib (CP-690,550) Is Absorbed And Moves Through The Body Following Oral Administration Of Tasocitinib (CP-690,550) Tablets To Healthy Subjects

Rheumatoid Arthritis

Singapore
Pharmacyclics Switzerland GmbH
Janssen Biotech, Inc., including Johnson & Johnson

Enrolling by invitation

Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.

Lymphoma, B-Cell | Lymphoma, Non-Hodgkin | Solid Tumor | Leukemia, B-cell | Graft Vs Host Disease

United States, Spain, Taiwan, United Kingdom, Australia, Italy, Russian Federation, Canada, New Zealand, Korea, Republic of, France, Turkey, Czechia, Hungary, Poland, Sweden
Janssen-Cilag Ltd.

Completed

A Study of Ibrutinib in the Treatment of Chronic Lymphocytic Leukemia and Mantle-cell Lymphoma in Routine Clinical Practice (FIRE)

Lymphoma, Mantle-Cell | Leukemia, Lymphocytic, Chronic, B-Cell

France
The Lymphoma Academic Research Organisation

Completed

Study of Ibrutinib in Patients With Relapsed or Refractory Primary Central Nervous Lymphoma or Intraocular Lymphoma (iLOC)

Intraocular Lymphoma | Primary Central Nervous Lymphoma

France
Gruppo Italiano Malattie EMatologiche dell'Adulto

Completed

Clinical-biological Characteristics and Outcome of Chronic Lymphocytic Leukemia Under Ibrutinib-named Patient Program

Chronic Lymphocytic Leukemia

Italy
Janssen-Cilag S.p.A.

Completed

A Study to Evaluate Ibrutinib Retention in Chronic Lymphocytic Leukemia Participants Treated in a Real World Setting (EVIdeNCE)

Leukemia, Lymphocytic, Chronic, B-Cell

Italy
The First Affiliated Hospital with Nanjing Medical...
Xian-Janssen Pharmaceutical Ltd.

Unknown

Observational Study of CLL/SLL Treatment and Ibrutinib Treatment of CLL/SLL in Routine Clinical Practice

Chronic Lymphocytic Leukemia | Small Lymphocytic Lymphoma

China
Pfizer

Terminated

Effect of 2-year Administration of CP-945,598 on Weight Loss Efficacy and Safety.

Obesity

Australia, United States, Korea, Republic of, Spain, France, United Kingdom, Germany, Sweden, Argentina, Chile, Mexico
Pfizer

Terminated

A Long-Term Study To Examine The Effects Of CP-945,598 On Weight Loss And Safety

Obesity

United States, Canada
Pfizer

Completed

A Study to Understand the Effect of Low-Fat and High-Fat Meals on the Medicine Called PF-07284890 in Healthy Adults

Healthy Participants

United States
Janssen Research & Development, LLC

Completed

A Crossover Study to Evaluate the Relative Oral Bioavailability and Food Effect After Single Dose Administration of JNJ-54861911 Tablet in Healthy Elderly Participants

Healthy

Belgium
Janssen Research & Development, LLC

Completed

A Study to Evaluate Bioavailability, Food Effect, Safety and Tolerability of a Solid Dosage Formulation of JNJ-54861911 in Healthy Older Male Participants

Healthy

Belgium
IRCCS San Raffaele

Recruiting

Real World Data on Ibrutinib Use in PCNSL Rel/Ref (ReWIPretro)

PCNSL

Italy
Memorial Sloan Kettering Cancer Center
Ohio State University; Pharmacyclics LLC.; Janssen Biotech, Inc.

Completed

Study of Ibrutinib in Relapsed and Refractory T-cell Lymphoma

T-cell Lymphoma | Relapsed and Refractory T-cell Lymphoma

United States

3

Subscribe